The Forrest plot in the Figure shows the results of the comparison of rivaroxaban versus warfarin as non-inferiority and/or superiority, for the 3 predefined methods of analysis in ROCKET AF.[97] This shows in graphic form that that rivaroxaban is noninferior to warfarin by both per-protocol and ITT analysis, and superior to warfarin by safety on-treatment analysis, just missing statistical superiority (p=0.12) in the ITT analysis.  Thus it appears that rivaroxaban is at least non-inferior to warfarin, and in some respects meets the superiority level seen with the other agents we are discussing.

 Reiffel JA. Am J Med 2013; 126: 00-00.